Vaxcyte Begins Phase 1 Clinical Trial for Group A Streptococcus Vaccine Candidate VAX-A1

Vaxcyte, Inc. has administered the first dose to a participant in a Phase 1 clinical trial evaluating the safety and immunogenicity of VAX-A1, an investigational vaccine candidate designed to prevent diseases caused by Group A Streptococcus (GAS). The study marks the initial human testing phase for the vaccine, which aims to address the global health burden associated with GAS infections.

The clinical trial enrolls healthy adults to assess how the human body responds to the vaccine candidate. Researchers will monitor participants for safety signals and evaluate the immune response generated by VAX-A1. Group A Streptococcus is responsible for a range of conditions, including strep throat, scarlet fever, and more severe invasive diseases. Currently, no vaccine exists to prevent GAS infections, and the development of VAX-A1 represents an effort to provide a preventative option for the public. The company expects the data from this Phase 1 study to inform the future development and potential clinical path for the vaccine candidate.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 2, 2026

Author

GOAI